SUBTYPED ACCORDING TO THREE DIAGNOSTIC SYSTEMS STANDARD DOSE ANTIPSYCHOTIC TREATMENT RESPONSE IN SCHIZOPHRENICS

Year 1994, Volume: 47 Issue: 1, 109 - 118, 03.06.1994

Behçet Coşar

https://izlik.org/JA92JD96NF

Abstract

No extrapyramidal side effects equivalent to a score of 0.4 or higher on the Simpson Extrapyramidal Side Effects Rating Scale were detected in any of the patients subtyped according to DSM III-R, T/W and N/P diagnostic systems during 30 days of treatment.

Keywords

Simpson , Extrapyramidal , Side Effects

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

ÜÇ TANI SİSTEMİNE GÖRE ALTTİPLENDİRİLMİŞ ŞİZOFRENLERDE STANDART DOZ ANTİPSİKOTİK TEDAVİYE YANIT

https://izlik.org/JA92JD96NF

Abstract

DSM III-R, T/W ve N/P tanı sistemlerine göre alttiplendirilen hastaların hiçbirinde, 30 günlük tedavi boyunca Simpson Ekstrapiramidal Yan Etki Ölçüm Ölçeği'nde 0.4 ve üzerinde puana eşdeğer ekstrapiramidal yan etki saptanmamıştır.

Keywords

Simpson , Ekstrapiramidal , Yan Etki

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Johnstone EC Owens DGC Frith CD Crow TJ: The relative stability of positive and negative features in chronic schizophrenia. Br J Psychiatry 1987, 150: 00-04.
• 2.Kaplan HI Sadock BJ Comprehensive Textbook of Psychiatry/V Baltimore Williams and Wilkins, 1909
• 3.Kay SR Singh MM: The positive-negative distinction in drug-free schizophrenic patients stability, response to neuroleptics and prognostic significance. Arch Gen Psychiatry 1900, 40: 711-718.
• 4.Klerman GL Kendell RE: Schizophrenia, Affective Disorders and Dementias Psychiatry: Chapter 52-53 ed. Guze S B. Halzer JE Lippincott Company NY 1968
• 5. Kolb LC Brodie HKH Schizophrenic Disorders Modern Clinical Psychiatry Chap- ter 18, Tenth Edition, WB Saunders Company USA 1982
• 6.Kolokowka T Williams AO Ardern Met al, Schizophrenia with good and poor outcome. Br J Psychiatry 1985, 148:229-246
• 7.Lehmann HE: Psychopharmacological treatment of schizophrenia. Schizophr Bull (Special issue: treatment) 1975, 13:27-45.
• 8.Liddle PF Prefrontal and subcortical dysfunction in schizophrenia International Perspectives in Schizophrenia Biological, Social and Epidemiological Findings Chapter 8 ed. Malcolm Weller, John Libbey and Co Ltd, UK 1990
• 9. Liddle PF Barnes TRE Morris D Haque S: Three syndrome in chronic schizoph renia. Br J Psychiatry 1989; 155 (suppl 7): 119-122
• 10.MacCap AVP Crow TJ: Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1900, 137: 379-382
• 11. Overall JE Gorham DE: The Brief Psychiatric Rating Scale. Psychol Rep 1961; 1001:10: 700-812.
• 12.Simpson GM Angus JWS: A rating scale for extrapyramidal side effects. Acta Psych Scand 1970; 212 (suppl 44)0-11.
• 13. Smith RC Crayton JW Tamminga C et al Blood levels of neuroleptic drugs. clinical response and plasma prolactin in chronic non-responding schizophrenic patients. The Kinetics of Psychiatric Drugs ed. JC Schoolar, JL. Clagborn Brun- ner/Mazel NY 1979
• 14.Tsuang MT Faraone SV Day M: Schizophrenic Disorders The New Harvard Gui- de to Psychiatry Chapter 13 ed. Armand M Jr The Belknap Press of Harvard University Press 1968.
• 15.Tsuang MT Winokur G: Criteria for subtyping schizophrenia: clinical differen tiation of hebephrenic and paranoid schizophrenis. Arch Psychiatry 1974; 3: 43-47
• 16.Van Kammen DP Hommes DW Malas KL Effect of pimozide on positive and negative symptoms in schizophrenic patients. Are negative symptoms state de pendent? Neuropsychobiology 1987, 18:113-117.
• 17. Yüksel N Köroğlu E Antipsikotik İlaçlar. Klinik Uygulamah Psikofarmakoloji Bölüm 2 Hekimler Yayın Birliği Ankara 1991